FDA mulls Elevidys market withdrawal following 3rd death after a Sarepta gene therapy

18th July 2025 Uncategorised 0

Although Sarepta initially appeared to have avoided the worst possible outcome for Elevidys—market withdrawal—thanks to the gene therapy’s new black box warning, the FDA is signaling stronger misgivings about the approved drug in the wake of a third patient death from an investigational treatment.

More: FDA mulls Elevidys market withdrawal following 3rd death after a Sarepta gene therapy
Source: fierce